Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
Top Cited Papers
- 13 May 2019
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 20 (6), 781-794
- https://doi.org/10.1016/s1470-2045(19)30152-4
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2015
- Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trialThe Lancet Oncology, 2014
- In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasoneLeukemia, 2014
- Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 studyBlood, 2014
- Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trialThe Lancet Oncology, 2013
- Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide–refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02Blood, 2013
- Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomideLeukemia, 2012
- Infections in Patients with Multiple Myeloma in the Era of High‐Dose Therapy and Novel AgentsClinical Infectious Diseases, 2009
- International uniform response criteria for multiple myelomaLeukemia, 2006
- Clinical Course of Patients With Relapsed Multiple MyelomaMayo Clinic Proceedings, 2004